NAMD Urges Congress to Address Break Through Drugs
In October 2014, NAMD called on Congress to provide new tools for states to manage prescription drug costs.
In October 2014, NAMD called on Congress to provide new tools for states to manage the exorbitant costs of specialty drugs entering the market. This letter was triggered by the introduction of curative hepatitis C therapies, which illustrate fundamental challenges in Medicaid drug coverage and reimbursement that need statutory solutions.
NAMD Comments on Medicare’s Proposed Coverage Determination for Alzheimer’s Drug
NAMD Urges CMS to Mitigate State Costs on Controversial Alzheimer’s Drug
Drop us your email and we’ll keep you up-to-date on Medicaid issues.